Clinical Trial Update: Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting [Phase 4]

View source ↗

Summary

Phase 4 trial comparing fosaprepitant (IV) to aprepitant for prevention of chemotherapy-induced nausea and vomiting; results were posted in 2015 in ovarian and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Uterine Cancer

Drugs mentioned

• EMEND (aprepitant)
• Emend IV (fosaprepitant)

Snippet

Sponsor: Gynecologic Oncology Associates | Conditions: Ovarian Cancer, Uterine Cancer | Phase 4 | Status: COMPLETED | Results posted: 2015-05-27